Adial Pharmaceuticals (ADIL) Insider LP Buys $65K of Stock

On June 29, Coastlands Capital LP acquired 25,000 shares of Adial Pharmaceuticals, Inc. (NasdaqCM: ADIL) at an average price of $2.60 per share. This purchase was valued at $65,000 and was not part of a pre-arranged plan.

Insider Buying and Selling at Adial Pharmaceuticals, Inc.

Coastlands Capital LP's recent acquisition is part of a series of insider transactions at Adial Pharmaceuticals. On June 12, Chief Development Officer Matt Davidson bought 232,417 shares, with additional purchases on June 11 and June 12 totaling 65,074 and 1,923 shares, respectively. Wendy Young also acquired 36,378 shares at $2.75 per share on June 12.

Other Institutional Activity in Adial Pharmaceuticals

Several other institutional investors have adjusted their positions in Adial Pharmaceuticals. Geode Capital Management, LLC increased its stake by 18,019 shares, bringing its total to 24,249 shares valued at approximately $43,405. Vanguard Fiduciary Trust Co opened a new position with 5,879 shares worth about $10,523. Meanwhile, Tower Research Capital LLC (TRC) increased its holdings by 1,302 shares to a total of 1,356 shares valued at $2,427. UBS Group AG also boosted its position by 175 shares, now holding 542 shares valued at $970.

Adial Pharmaceuticals, Inc. Stock Down 47.3%

Shares of Adial Pharmaceuticals traded near $2.56 on Wednesday. The company's market capitalization stands at approximately $5.6 million. Adial has a 52-week low of $1.31 and a high of $19.00, with a 50-day moving average of $2.05 and a 200-day moving average of $4.87. The company has a beta of 1.459, indicating higher volatility compared to the market.

Analysts Set New Price Targets

On June 15, Lucid Capital Markets initiated coverage on Adial Pharmaceuticals with a 'buy' rating and a price target of $6.00. Maxim Group had previously upgraded the stock to a 'buy' with a target of $1.50 on September 30, 2025. The consensus among analysts, with two opinions, is a 'buy' recommendation, with a mean price target of $7.00.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Glen Allen, Virginia. It focuses on developing treatments for addiction and related disorders. The company's main product, AD04, is undergoing Phase 3 clinical trials for alcohol use disorder. Adial is also working on developing non-opioid pain reduction therapies and other drug candidates.

Bottom Line

Coastlands Capital's recent purchase of Adial Pharmaceuticals shares reflects continued insider interest in the company. While this insider activity suggests confidence, it's important for investors to consider the company's volatile stock history and ongoing product development. Remember, 13F filings and insider transactions provide a snapshot of past actions and may not indicate current positions.